<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03053115</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT: 2016-000687-41</org_study_id>
    <nct_id>NCT03053115</nct_id>
  </id_info>
  <brief_title>Combined Replacement Therapy With Levothyroxine and Liothyronine in Thyroidectomized Patients</brief_title>
  <acronym>LEVOLIO</acronym>
  <official_title>Combined Replacement Therapy With Levothyroxine and Liothyronine in Thyroidectomized Patients: Effects on Peripheral Tissues. A Prospective, Randomized, Controlled, Double-blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda USL Modena</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda USL Modena</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the peripheral tissue response to the combined
      administration of levothyroxine (LT4) and liothyronine (LT3) in hypothyroid patients with
      residual thyroid function virtually absent (thyroidectomized). Cases will be treated with
      LT4+LT3, at personalized doses according to clinical guidelines and respecting the circadian
      rhythmicity of LT3 and the physiological T3/T4 ratio. Controls will be treated with LT4 and
      placebo. Treatment duration: 24 weeks.

      The primary endpoint will be the peripheral effect of thyroid hormones, measuring tissue
      markers levels, such as thyroid stimulating hormone(TSH), sex hormone binding globulin
      (SHBG), total cholesterol, LDL cholesterol, lipoprotein A, osteocalcin, urinary
      N-telopeptide, ferritin, myoglobin, creatine kinase, glucose 6 phosphate dehydrogenases,
      angiotensin-converting enzyme (ACE). The secondary endpoints are bone and metabolic
      modifications, evaluated by DEXA, quality of life, tissue specific miRNA expression,
      polymorphisms of genes involved in thyroid hormones metabolism.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 14, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change from baseline TSH serum levels at 12 and 24 weeks (microIU/ml)</measure>
    <time_frame>baseline and then repeated at 12 weeks and 24 weeks</time_frame>
    <description>change from baseline TSH serum levels at 12 and 24 weeks (microIU/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change from baseline free triiodothyronine (fT3) serum levels at 12 and 24 weeks (pmol/L)</measure>
    <time_frame>baseline and then repeated at 12 weeks and 24 weeks</time_frame>
    <description>change from baseline free triiodothyronine (fT3) serum levels at 12 and 24 weeks (pmol/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change from baseline free levothyroxine (fT4) serum levels at 12 and 24 weeks (pmol/L)</measure>
    <time_frame>baseline and then repeated at 12 weeks and 24 weeks</time_frame>
    <description>change from baseline free levothyroxine (fT4) serum levels at 12 and 24 weeks (pmol/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change from baseline SHBG serum levels at 12 and 24 weeks (nmol/L)</measure>
    <time_frame>baseline and then repeated at 12 weeks and 24 weeks</time_frame>
    <description>change from baseline SHBG serum levels at 12 and 24 weeks (nmol/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change from baseline total cholesterol serum levels at 12 and 24 weeks (mg/dl)</measure>
    <time_frame>baseline and then repeated at 12 weeks and 24 weeks</time_frame>
    <description>change from baseline total cholesterol serum levels at 12 and 24 weeks (mg/dl)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change from baseline LDL cholesterol serum levels at 12 and 24 weeks (mg/dl)</measure>
    <time_frame>baseline and then repeated at 12 weeks and 24 weeks</time_frame>
    <description>change from baseline LDL cholesterol serum levels at 12 and 24 weeks (mg/dl)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change from baseline lipoprotein (a) serum levels at 12 and 24 weeks (mg/dl)</measure>
    <time_frame>baseline and then repeated at 12 weeks and 24 weeks</time_frame>
    <description>change from baseline lipoprotein (a) serum levels at 12 and 24 weeks (mg/dl)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change from baseline urinary N-telopeptide levels at 12 and 24 weeks (nmol/mmol creatinine)</measure>
    <time_frame>baseline and then repeated at 12 weeks and 24 weeks</time_frame>
    <description>change from baseline urinary N-telopeptide levels at 12 and 24 weeks (nmol/mmol creatinine)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change from baseline ferritin serum levels at 12 and 24 weeks (ng/ml)</measure>
    <time_frame>baseline and then repeated at 12 weeks and 24 weeks</time_frame>
    <description>change from baseline ferritin serum levels at 12 and 24 weeks (ng/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change from baseline myoglobin serum levels at 12 and 24 weeks (microgr/L)</measure>
    <time_frame>baseline and then repeated at 12 weeks and 24 weeks</time_frame>
    <description>change from baseline myoglobin serum levels at 12 and 24 weeks (microgr/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change from baseline creatine kinase serum levels at 12 and 24 weeks (mU/mL)</measure>
    <time_frame>baseline and then repeated at 12 weeks and 24 weeks</time_frame>
    <description>change from baseline creatine kinase serum levels at 12 and 24 weeks (mU/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change from baseline glucose-6-phosphate dehydrogenases serum levels at 12 and 24 weeks (U/gHb)</measure>
    <time_frame>baseline and then repeated at 12 weeks and 24 weeks</time_frame>
    <description>change from baseline glucose-6-phosphate dehydrogenases serum levels at 12 and 24 weeks (U/gHb)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change from baseline ACE serum levels at 12 and 24 weeks (mc/L)</measure>
    <time_frame>baseline and then repeated at 12 weeks and 24 weeks</time_frame>
    <description>change from baseline ACE serum levels at 12 and 24 weeks (mc/L)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>weight (kg)</measure>
    <time_frame>baseline and then repeated at 6, 12 weeks and 24 weeks</time_frame>
    <description>weight measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>height (cm)</measure>
    <time_frame>baseline</time_frame>
    <description>height measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>baseline and then repeated at 24 weeks</time_frame>
    <description>Bone Densitometry (DEXA) total body</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone composition</measure>
    <time_frame>baseline and then repeated at 24 weeks</time_frame>
    <description>Bone Densitometry (DEXA) at lumbar spine and hip</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life changes</measure>
    <time_frame>baseline and then repeated at 12 weeks and 24 weeks</time_frame>
    <description>score at validated questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline tissue specific miRNA expression at 12 and 24 weeks</measure>
    <time_frame>baseline and then repeated at 12 weeks and 24 weeks</time_frame>
    <description>change from baseline tissue specific miRNA expression at 12 and 24 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Hypothyroidism</condition>
  <arm_group>
    <arm_group_label>CASES</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treatment with levothyroxine and liothyronine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CONTROLS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment with levothyroxine and placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liothyronine</intervention_name>
    <description>Cases will take liothyronine drops in the morning and two hours after dinner</description>
    <arm_group_label>CASES</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levothyroxin</intervention_name>
    <description>Both cases and controls will take levothyroxine in the morning (entire dose for controls, reduced dose for cases)</description>
    <arm_group_label>CASES</arm_group_label>
    <arm_group_label>CONTROLS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Controls will take placebo two hours after dinner</description>
    <arm_group_label>CONTROLS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  older than 18 years

          -  capable of consent

          -  able to fill in a questionnaire in italian

          -  thyroidectomized

          -  serum thyroglobulin levels below 0.2 ng/ml and antibodies anti-thyroglobulin
             undetectable (below normal range)

          -  well treated taking stable doses of levothyroxine in tablets, in the previous 3 months

        Exclusion Criteria:

          -  TSH suppressive therapy

          -  pregnancy

          -  cardiac arrhythmias

          -  severe liver, kidney or bone diseases

          -  ongoing steroids treatment

          -  ongoing or in the previous 12 months treatment with bone anti-resorptive, amiodarone,
             colestyramine or iron.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AziendaUSLModena</name>
      <address>
        <city>Modena</city>
        <zip>41126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuela Simoni, MD, PhD</last_name>
      <phone>00390593961806</phone>
      <email>manuela.simoni@unimore.it</email>
    </contact>
    <investigator>
      <last_name>Manuela Simoni, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2016</study_first_submitted>
  <study_first_submitted_qc>February 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2017</study_first_posted>
  <last_update_submitted>March 20, 2017</last_update_submitted>
  <last_update_submitted_qc>March 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda USL Modena</investigator_affiliation>
    <investigator_full_name>Manuela Simoni</investigator_full_name>
    <investigator_title>Director of the Unit of Endocrinology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypothyroidism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

